close

From case studies to common practice: a roadmap for precision oncology in Europe (Guest blog)

Cancer is currently the second leading cause of death in Europe and is projected to become the number one killer by 2035. Precision oncology, which customizes cancer care to the genetic profile of an individual tumor, offers hope for patients. By using molecular and genomic information to guide treatment decisions, precision oncology can help identify patients most likely to benefit from specific therapies, reduce exposure to ineffective treatments and unnecessary side effects, and support more efficient use of healthcare resources. Precision oncology is moving beyond specialist centers to be part of multidisciplinary cancer care at cancer centers across Europe.

However, these advances are not reaching all European patients equally. Awareness of genomic testing varies sharply between countries and even within them. Laboratories may meet high technical standards while the pathway from a test result to an accessible, reimbursed therapy remains unclear. And even when a biomarker test and its matched treatment are both validated, separate budgets, timelines and approval processes for diagnostics and medicines can delay routine access for years.

Ensuring patients have access to genomic testing, molecular tumor boards and biomarker-guided treatments require awareness across stakeholders, a well-functioning infrastructure and trained workforce and adequate funding and reimbursement. The EU has promising areas of world-class precision oncology, but too many patients are still missing out.

To help improve the concrete implementation of precision oncology, addressing the issues identified on the ground and disseminating best practices, the Precision Oncology workstream of EFPIA’s Oncology Platform developed a comprehensive white paper titled "Advancing precision oncology treatment and testing across Europe". The white paper was built with the input of clinicians, regional health authorities, patient representatives, health economists, academics and industry experts via interviews, bilateral meetings and a workshop.

Matthijs Van Meerveld

Matthijs Van Meerveld is Associate Vice President and Global Head of Patient Advocacy and Policy at Menarini Stemline....
Read Morechevron_right

Olivia McDermid

Olivia McDermid is the International Oncology Health Policy Director at Amgen, where she leads oncology policy...
Read Morechevron_right
Download the report Advancing Precision Oncology Treatment And Testing Across Europe

Applying the framework to address real world challenges

The white paper highlights that building future-ready, innovation-backed health ecosystems relies on addressing three central pillars: 1) awareness, 2) infrastructure and workforce and 3) funding and reimbursement.

The paper then outlines 15 case studies where healthcare authorities in different countries have dealt with issues concerning these pillars, what measurable outcomes they have generated, their strengths, challenges and how they could further develop and scale or transfer.

Perhaps the most interesting part of the analysis is the 18 recurring problem patterns, or “archetypes,” which outline structural bottlenecks that return time after time in various settings. Each archetype is linked to case studies that have faced the same issue. For example, the Belgian ComPerMed model shares insights for addressing siloed budgets, while Emilia-Romagna and Catalonia provide examples of managing within regional fragmentation.

The report then distills 13 recommendations from the case studies, for a clear overview of what a best practice precision oncology setting can look like. They range from ensuring that guidelines and protocols are disseminated, patient voices are institutionally included, infrastructure inequity is tackled, and test funding is sustainable and timely.

Next steps: to Poland and beyond

After a successful launch event in collaboration with Farmaindustria in Toledo, Spain earlier this year, the next step for the Precision Oncology workstream is applying the framework in Poland in collaboration with INFARMA through a multi-stakeholder workshop on November 26th. We will examine the specific barriers to implementation, identifying relevant archetypes together with national stakeholders to translate the toolkit into a concrete action plan for Poland. That is just the beginning. The framework was designed for any local or regional healthcare decision maker to diagnose and plan. With the EU-levers already in place, such as the Europe’s Beating Cancer Plan and other existing supporting instruments, the framework offers practical tools to turn ambition into action.

The EU already has scientific excellence, clinical expertise and many examples of what has worked. This paper invites the reader to find the archetype that matches his or her specific system, learn from who has already addressed these issues – and how – and help bring precision oncology within reach of the patient, wherever they live.